Back to homepage

Tag "breast cancer"

Leptomeningeal carcinomatosis and breast cancer: a systematic review of current evidence on diagnosis, treatment and prognosis

Authors: Ludovica Mollica, Claudia Leli, Silvia Puglisi, Silvia Sardi, Federico Sottotetti

This article is a systematic review of the evidence published over the last two decades, focusing on recent advances in the diagnostic
and therapeutic options of leptomeningeal carcinomatosis.

More

Experience with ospemifene in patients with vulvar and vaginal atrophy and a history of breast cancer: case studies

Authors: Mariella Lilue MD, Santiago Palacios MD, PhD, María del Carmen Pingarrón Santofimia MD

Women with breast cancer are at a higher risk of developing vulvar and vaginal atrophy (VVA). Ospemifene is approved to treat VVA in postmenopausal women with a history of breast cancer after completion of all breast cancer (including adjuvant) treatments. This article examines the background characteristics and outcomes in two postmenopausal women with a history of breast cancer who were treated with ospemifene for VVA.

More

A paradigm shift for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer: a review of CDK inhibitors

Authors: Mariane Teodoro Fernandes MD, Jacob J Adashek BA, Carmelia Maria Noia Barreto MD, Ana Cláudia Barbin Spinosa MD, Barbara de Souza Gutierres MSc, Gilberto Lopes MD, MBA, FAMS, Auro del Giglio MD, PhD, Pedro Nazareth Aguiar Jr MD, MSc

A novel class of targeted therapy has been approved for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer. There are currently three approved agents, which are oral cyclin-dependent kinase 4/6 (CDK4/6) inhibitors. In this review, all available data is summarized, unanswered questions are highlighted, and pharmacological differences between each CDK4/6 inhibitor are discussed.

More

Advances in the use of PARP inhibitor therapy for breast cancer

Authors: Kelly E McCann MD, PhD, Sara A Hurvitz MD

In the care of oncology patients, poly-ADP-ribose polymerase (PARP) inhibitors are best known as a semitargeted treatment
for BRCA1- and BRCA2-associated ovarian and breast cancers, this article reviews the broader understanding of PARP biology that has spurred interest in expanding their clinical utility.

More

Harnessing the immune system in the battle against breast cancer

Authors: Elizabeth S Nakasone MD, PhD, Sara A Hurvitz MD, Kelly E McCann MD, PhD

This article examines the major approaches to immunotherapy in breast cancers, both successes and failures, as well as new therapies on the horizon.

More